Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN
Woodley Farra Manion Portfolio Management Inc. decreased its stake in AstraZeneca PLC by 1.0% in the third quarter of last year, holding 752,814 shares valued at $57.76 million. Despite this slight reduction, other institutional investors have increased their positions in AZN. Analysts have largely maintained a "Buy" or "Overweight" rating on AstraZeneca, with an average target price of $95.75, and the company recently announced a dividend payment.
Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026
Abbott Laboratories (ABT) shares are trading around $112, reflecting a 16% pullback from recent highs due to a FreeStyle Libre 3 sensor recall and weakness in the Nutrition segment. Despite these headwinds, the company's Medical Devices segment remains strong, and upcoming catalysts including the Exact Sciences acquisition and the Volt PFA launch have analysts projecting a mean price target of $133.39.
Wealthcare Advisory Partners LLC Buys 19,612 Shares of AstraZeneca PLC $AZN
Wealthcare Advisory Partners LLC significantly increased its stake in AstraZeneca PLC, purchasing 19,612 shares to own a total of 23,126 shares valued at $1.774 million. Other institutional investors also adjusted their holdings in AstraZeneca. The company recently declared a dividend of $1.595 per share, payable on March 23rd, and maintains a "Moderate Buy" average analyst rating.
Edwards Lifesciences Stock at $78: Here’s the Analysts’ Bull Case Scenario
Edwards Lifesciences (EW) shares recently rose 4% to $78.92 after a stronger-than-expected Q4 earnings report, with revenue of $1.57 billion driven by strong TAVR and TMTT sales. The company's future looks promising with raised EPS guidance, new product launches, and a shifting market perception from a single-product company to a multi-therapy structural heart platform. Analysts have a mean price target of $96.50, implying a 22% upside, and a DCF model suggests a 70.4% total return by 2030, indicating the stock is potentially undervalued.
Factory Mutual Insurance Co. Acquires Shares of 57,852 AstraZeneca PLC $AZN
Factory Mutual Insurance Co. has acquired 57,852 shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, valued at approximately $4.438 million. AstraZeneca recently announced a dividend of $1.595 per share, payable on March 23rd, with a record date of February 20th and an ex-dividend date also on February 20th, representing a dividend yield of 153.0%. The company's stock opened at $208.76, has a market cap of $323.77 billion, and an average analyst rating of "Moderate Buy" with a target price of $95.75.
AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board
Ontario Teachers Pension Plan Board significantly reduced its stake in AstraZeneca PLC by 41.0% in Q3 2025, selling 569,294 shares, though AstraZeneca remains one of its largest holdings. Meanwhile, other institutional investors like CIBC World Market, Y Intercept Hong Kong, and Oxbow Advisors increased their positions in the company. AstraZeneca recently announced a dividend of $1.595 per share, payable March 23, and analysts maintain a "Moderate Buy" rating with an average price target of $95.75.
Edwards Lifesciences CFO set for back-to-back global healthcare talks
Edwards Lifesciences Corporation (NYSE: EW) announced that its CFO, Scott Ullem, is scheduled to present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, and the Leerink Global Healthcare Conference on March 11, 2026. Live webcasts of both presentations will be available on the company's investor relations website. Edwards Lifesciences is a leading global structural heart innovation company focused on improving patient lives through breakthrough technologies.
Alberta Investment Management Corp Buys Shares of 68,300 Edwards Lifesciences Corporation $EW
Alberta Investment Management Corp acquired a new stake of 68,300 shares in Edwards Lifesciences Corporation (NYSE:EW) during the third quarter, valued at approximately $5.31 million. Institutional investors now hold about 79.46% of the company's stock, while insiders have recently sold shares worth $3.70 million. Analysts currently have a "Moderate Buy" consensus rating with an average target price of $96.14 for Edwards Lifesciences.
Medtronic plc (NYSE:MDT) Q3 2026 Earnings Call Transcript
Medtronic plc reported strong Q3 2026 earnings, exceeding expectations with 6% organic revenue growth and EPS of $1.36. The company highlighted significant progress in its four generational growth drivers: PFA platform for AFib, Symplicity Spyral for hypertension, Altaviva for urinary incontinence, and the Hugo surgical robot. Medtronic reaffirmed its fiscal 2026 organic revenue growth guidance of approximately 5.5% and committed to high single-digit EPS growth for fiscal year 2027, driven by accelerated growth and strategic investments.
PNC Financial Services Group Inc. Raises Stock Position in AstraZeneca PLC $AZN
PNC Financial Services Group Inc. significantly increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 4.1% during the third quarter, acquiring an additional 9,904 shares to hold a total of 250,986 shares valued at $19.256 million. AstraZeneca recently declared a dividend of $1.595 per share, payable on March 23rd, with the ex-dividend date set for February 20th. The stock currently trades around $209.39, boasting a market capitalization of $324.74 billion, and has a consensus "Moderate Buy" rating from analysts with an average target price of $95.75.
Cardiovascular Devices Market Booming Rapidly from 2026 to 2033
The Cardiovascular Devices market is projected to grow significantly, from USD 66,420.8 million in 2025 to USD 1,12,366.1 million by 2032, at a CAGR of 7.8%. A new report from Coherent Market Insights details this growth, analyzing market dynamics, key players like Livanova PLC and Medtronic PLC, and regional trends, with forecasts extending to 2033. The study aims to provide stakeholders with insights into market opportunities and challenges across various segments.
Edwards Lifesciences Corp. Drops ‘Anti-Copycatting’ Policy Amid EU Probe
Edwards Lifesciences Corp. has dropped its controversial "anti-copycatting" policy, leading the European Commission to close its antitrust investigation into the medical device maker. The policy, which governed relations with clinicians and distributors working with rival companies, was scrutinized for potentially distorting competition. While the probe is closed, the Commission noted this does not endorse Edwards' past conduct.
Vanguard Group Inc. Increases Stock Position in Becton, Dickinson and Company $BDX
Vanguard Group Inc. has increased its stake in Becton, Dickinson and Company (BDX) by 0.5% in the third quarter, now owning 32,455,790 shares valued at approximately $6.07 billion, representing 11.32% of the company. Despite beating quarterly earnings expectations with $2.91 EPS and $5.25 billion in revenue, Becton, Dickinson and Company provided conservative FY2026 guidance below analyst estimates. The company declared a quarterly dividend of $1.05 and authorized a $10 million share repurchase plan, while analysts maintain a "Hold" rating with an average target price of $195.46.
Edwards Lifesciences Corporation $EW Shares Sold by PNC Financial Services Group Inc.
PNC Financial Services Group Inc. reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.7% in the third quarter, selling 15,439 shares. Despite this, institutional and hedge fund ownership remains high at 79.46%, with several other large funds increasing their positions. Edwards Lifesciences reported mixed Q4 earnings, missing EPS estimates but exceeding revenue, and provided Q1 2026 guidance, while analysts on average maintain a "Moderate Buy" rating with a target price of $96.14.
ABN Amro Investment Solutions Sells 11,020 Shares of Zimmer Biomet Holdings, Inc. $ZBH
ABN Amro Investment Solutions recently reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 31.6%, selling 11,020 shares, and now holds 23,860 shares valued at approximately $2.35 million. This move comes as Zimmer Biomet reported strong quarterly results, surpassing EPS and revenue expectations, and provided encouraging FY2026 guidance. Despite ABN Amro's reduction, institutional interest remains high, with Rakuten Investment Management Inc. opening a significant new position.
3 Reasons to Avoid NVST and 1 Stock to Buy Instead
This article advises investors to avoid Envista Holdings Corp (NVST) despite its recent stock performance. The author highlights three main reasons: disappointing long-term revenue growth, previous growth initiatives losing money due to negative ROIC, and a decline in new investment returns. Instead, the article suggests looking into the most entrenched endpoint security platform on the market and provides a link to "Top 6 Stocks" list.
Edwards Lifesciences scraps anti-copycat policy, EU drops antitrust investigation
Edwards Lifesciences, a U.S. medical device maker, has withdrawn its "Global Unilateral Pro-Innovation (Anti-Copycatting) Policy" after a complaint from Indian rival Meril, leading the EU antitrust regulators to close their investigation. The European Commission had been investigating the company over concerns of market power abuse since September 2023. The withdrawal of this policy has resolved the investigated concerns, preventing potential fines of up to 10% of global annual turnover for Edwards Lifesciences.
Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update
Edwards Lifesciences (EW) received a reiterated Buy rating and $110 price target from Stifel following its Q4 2025 earnings report. The company's sales increased by 11.6% to $1.57 billion, surpassing estimates, largely driven by a 10.6% year-over-year growth in transcatheter aortic valve replacement (TAVR) sales. Despite an EPS miss due to higher administrative costs, management maintained its 2026 financial outlook, anticipating controlled spending and sustained strong TAVR growth.
Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update
Edwards Lifesciences Corporation (EW) received a reaffirmed Buy rating and $110 price target from Stifel following its Q4 2025 earnings report. The company surpassed sales estimates with an 11.6% increase to $1.57 billion, primarily driven by strong transcatheter aortic valve replacement (TAVR) sales. Despite missing EPS expectations due to higher-than-anticipated sales and administrative costs, management maintained its 2026 financial outlook, anticipating controlled spending and continued TAVR growth.
10 Best Medical Technology Stocks to Invest In
This article highlights STERIS plc (NYSE: STE) as one of the best medical technology stocks to invest in, noting its strong Q3 FY2026 financial results. STERIS exceeded revenue expectations and matched profit forecasts, demonstrating significant year-over-year growth and reaffirming its full-year guidance. The company, which specializes in infection prevention and procedural support, showcased robust organic revenue growth driven by demand across various business lines.
Needham reiterates Buy rating on AtriCure stock amid competition By Investing.com
Needham has reiterated a Buy rating and a $45.00 price target on AtriCure Inc. (NASDAQ: ATRC) despite upcoming competition in the left atrial appendage closure (LAAC) market from Edwards Lifesciences. The firm highlights AtriCure's strong revenue growth and financial health, suggesting its established market position and specialized tools will help maintain growth even with new entrants. Other analysts have varied perspectives, with some downgrades due to competitive concerns, while others maintain optimistic ratings based on clinical trial potential.
Edwards Lifesciences CFO at Citi medtech, life sciences access day Feb. 26
Edwards Lifesciences announced that its chief financial officer, Scott Ullem, will present at Citi's 2026 Unplugged Medtech and Life Sciences Access Day on February 26, 2026, at 10:15 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version to follow. The company, known for its structural heart innovation, aims to improve patient lives through its technologies and partnerships.
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day
Edwards Lifesciences Corporation announced its participation in Citi’s 2026 Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, CFO, will present at 10:15 a.m. ET, with a live webcast available on the company's investor relations website and an archived version later the same day. Edwards Lifesciences is a global leader in structural heart innovation, committed to improving patient lives through breakthrough technologies and partnerships.
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day
Edwards Lifesciences (NYSE: EW) announced its participation in Citi’s 2026 Unplugged Medtech and Life Sciences Access Day. Scott Ullem, the company's chief financial officer, is scheduled to present on February 26, 2026, at 10:15 a.m. ET. A live webcast and archived version of the presentation will be available on the company's investor relations website.
Cibc World Market Inc. Lowers Stake in Parker-Hannifin Corporation $PH
Cibc World Market Inc. has reduced its stake in Parker-Hannifin Corporation by 17% in the third quarter of 2025, selling 3,458 shares and now holding 16,910 shares valued at $12.82 million. This move comes as company insiders have also been selling shares, totaling 5,825 shares worth $5.39 million over the past 90 days. Despite the institutional and insider selling, Parker-Hannifin reported strong quarterly earnings, beating EPS expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $990.47, while the company also declared a $1.80 quarterly dividend.
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Analysts
Edwards Lifesciences Corporation (NYSE:EW) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $96.14. Despite mixed Q4 results where revenue beat estimates but EPS missed, the company provided Q1 2026 guidance. Insider selling occurred last quarter, but institutional ownership remains high, and several analysts have raised their price targets.
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day
Edwards Lifesciences (NYSE: EW) announced its participation in Citi’s 2026 Unplugged Medtech and Life Sciences Access Day. Chief Financial Officer Scott Ullem is scheduled to present on February 26, 2026, at 10:15 a.m. ET. A live webcast and archived version of the presentation will be available on the company's investor relations website.
Needham reiterates Buy rating on AtriCure stock amid competition
Needham has reaffirmed its Buy rating and a $45.00 price target for AtriCure Inc. (NASDAQ:ATRC), despite impending competition from Edwards Lifesciences in the left atrial appendage closure (LAAC) market. The firm anticipates AtriCure will maintain low-teens overall revenue growth, citing the company's past resilience to competition and potential disadvantages for Edwards Lifesciences in the surgical LAAC market. AtriCure recently reported a 13% increase in Q4 2025 revenue, and analysts hold varied perspectives on its future amid competitive pressures.
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations
Artivion (NYSE:AORT) reported Q4 CY2025 revenue of $116 million, missing analyst estimates but showing a 19.2% year-on-year increase. The company's full-year revenue guidance exceeded expectations, and its non-GAAP EPS was in line with consensus. Despite the revenue miss and a slight dip in stock price post-announcement, Artivion showcased strong adjusted constant currency revenue growth for the full year 2025 and improved operating margins.
How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025
Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full-year 2025 sales of US$6.07 billion, with lower net income despite double-digit revenue growth. The company's 2026 guidance projects 8%-10% sales growth and EPS of US$2.90–US$3.05, driven by expanding TAVR and TMTT valve portfolios. This guidance is central to the investment narrative, as it will demonstrate whether Edwards can overcome profitability pressures from rising costs, tariffs, and R&D spending with increased sales volumes.
Johnson Investment Counsel Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Johnson Investment Counsel Inc. significantly reduced its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 38.3% in the third quarter, selling 17,924 shares and valuing its remaining holdings at $2.85 million. Despite this, other institutional investors increased their positions, and analysts have mixed ratings on the stock, with an average "Hold" and a consensus price target of $106.45. Zimmer Biomet recently reported strong Q4 earnings, beating estimates with $2.42 EPS and $2.24 billion in revenue, and announced a new share repurchase program.
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC is investigating whether officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to long-term shareholders. The firm encourages current shareholders to contact them to discuss potential legal rights, including corporate governance reforms or financial relief. This action aims to enhance shareholder value through improved company policies and oversight.
Needham reiterates Buy rating on AtriCure stock amid competition
Needham has reiterated a Buy rating and a $45.00 price target for AtriCure Inc. (NASDAQ:ATRC), despite anticipated competition in the left atrial appendage closure market from Edwards Lifesciences. The firm highlights AtriCure's resilience to past competition and its strong revenue growth, expecting it to maintain low-teens overall revenue growth. AtriCure also reported a 13% revenue increase in Q4 2025, though analyst opinions are mixed regarding future performance amid competitive pressures.
AtriCure stock maintains Market Outperform rating at Citizens despite Edwards competition
Citizens has maintained its "Market Outperform" rating and a $60.00 price target for AtriCure Inc. (NASDAQ:ATRC), even as competitor Edwards Lifesciences prepares to introduce a new surgical LAAC technology. Despite a 15% stock drop following Edwards' announcement, AtriCure demonstrates strong fundamentals with a 3.87 current ratio and 15.8% revenue growth. Analysts have mixed views, with JPMorgan downgrading to Neutral due to competition, while Piper Sandler maintains an Overweight rating, citing the potential of AtriCure's BoxX-NoAF clinical trial.
Wells Fargo Raises Price Target for Edwards Lifesciences (EW)
Wells Fargo maintained an "Overweight" rating on Edwards Lifesciences (EW) and increased its price target from $96.00 to $100.00. This adjustment reflects positive market sentiment, consistent with several other analysts who have also recently raised their price targets for the company. Edwards Lifesciences, a leader in medical devices for structural heart disease, shows strong market confidence with an average brokerage recommendation of "Outperform."
ZoomInfo Technologies Stock Under Pressure in February: Here’s the Path to $12 by Year-End
ZoomInfo Technologies (GTM) stock dropped over 10% after its Q4 2025 earnings report, despite beating estimates, due to weak 2026 guidance forecasting only 1% growth. The company, which provides a go-to-market intelligence platform, has authorized a $1 billion share repurchase program and aims for growth through AI products and an upmarket strategy. Investors are concerned about flat growth guidance and execution risks but note the strong profitability and share buyback add credibility.
AtriCure (ATRC) Shares Fall 15% Following JPMorgan Downgrade
AtriCure (ATRC) experienced a 15% drop in share price after JPMorgan downgraded the stock from Overweight to Neutral, reducing its price target from $48 to $36. This downgrade was largely due to anticipated competitive pressure from Edwards Lifesciences (EW), which plans to introduce a competing surgical product. While AtriCure demonstrates strong financial health with robust revenue growth and a solid balance sheet, it faces profitability challenges and increased market volatility.
Edwards Lifesciences Corp (NYSE:EW) Issues Upbeat Guidance
Edwards Lifesciences (NYSE:EW) stock rose after providing upbeat guidance, despite a slight earnings miss in its Q4 FY25 results. The company's TAVR business saw significant growth, along with its TMTT division. Edwards expects continued growth in 2026, driven by clinical trial results, new guidelines, and product approvals, with strong financial projections for both Q1 and the full year.
Piper Sandler Raises Price Target for Edwards Lifesciences (EW) to $100 | EW Stock News
Piper Sandler analyst Adam Maeder reaffirmed an 'Overweight' rating for Edwards Lifesciences (EW) and increased the price target from $98.00 to $100.00. This adjustment reflects continued confidence in the medical device company's performance. Several other analysts have also raised their price targets for EW, indicating a generally positive outlook and potential for growth, with an average target price of $96.09 among 31 analysts.
Rothschild & Co Redburn Adjusts Edwards Lifesciences PT to $94 From $93, Maintains Buy Rating
Rothschild & Co Redburn has increased its price target for Edwards Lifesciences from $93 to $94, while maintaining a Buy rating on the stock. This adjustment comes amidst various other analyst revisions for Edwards Lifesciences, with several firms updating their price targets and ratings. The company recently reported its Q4 2025 earnings, with revenue rising but adjusted EPS declining.
Edwards focuses on earlier TAVR adoption
Edwards Lifesciences is seeing accelerated sales of its transcatheter aortic valve replacement (TAVR) devices, driven by new study data supporting earlier use of its Sapien heart valves in asymptomatic patients with severe aortic stenosis. The company reported double-digit TAVR sales growth for the second consecutive quarter and anticipates a final decision from CMS in Q4 regarding expanded Medicare coverage for asymptomatic severe aortic stenosis. Edwards is also expanding its TMTT portfolio with new Pascal and Evoque devices and introducing Sapien M3 for mitral regurgitation.
Stifel reiterates Buy rating on Edwards Lifesciences stock at $110 target
Stifel has reiterated a Buy rating on Edwards Lifesciences (NYSE: EW) with a $110 price target, suggesting a 27% upside. The medical device company exceeded revenue expectations in Q4 2025, driven by strong TAVR sales, despite missing EPS estimates due to higher SG&A spending. Management maintains its financial guidance, anticipating continued TAVR growth and more measured spending in 2026.
JPMorgan downgrades AtriCure stock rating to Neutral on Edwards competition
JPMorgan downgraded AtriCure Inc. (NASDAQ:ATRC) from Overweight to Neutral and reduced its price target to $36.00 due to anticipated competition from Edwards Lifesciences, which plans to launch a competing surgical left atrial appendage closure product. Although AtriCure has previously shown resilience against competition, JPMorgan is concerned about Edwards' significant presence in the cardiac surgery market, which could pressure AtriCure shares in the near term. This comes as AtriCure recently reported a 13% revenue increase for Q4 2025, and Piper Sandler reiterated an Overweight rating, highlighting the potential impact of the BoxX-NoAF clinical trial.
Wells Fargo & Company Raises Edwards Lifesciences (NYSE:EW) Price Target to $100.00
Wells Fargo & Company has increased its price target for Edwards Lifesciences (NYSE:EW) to $100, maintaining an "overweight" rating, which suggests a 32.20% upside. This follows Edwards Lifesciences reporting Q4 revenue above estimates but missing on adjusted EPS, along with an optimistic 2026 outlook. Despite analyst bullishness, the report highlighted insider selling and signs of margin pressure as potential near-term concerns.
BTIG Reiterates Buy Rating for Edwards Lifesciences (EW) | EW St
BTIG has reaffirmed its "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD, reflecting confidence in the company's growth potential. This decision aligns with a generally positive outlook from other analysts, who have also maintained or upgraded their ratings and raised target prices for the medical device company. Edwards Lifesciences, a leader in structural heart disease devices, sees an average analyst target price of $96.09, suggesting a potential upside of 24.71% from its current price.
Edwards Lifesciences Corporation (NYSE:EW) Q4 2025 Earnings Call Transcript
Edwards Lifesciences (NYSE:EW) reported strong Q4 and full-year 2025 results, with sales growth of 11.6% and 10.7% respectively, driven by its focus on Structural Heart and innovations in TAVR and TMTT. The company remains confident in its 2026 sales and EPS guidance, anticipating continued growth from new therapies, expanded indications, and a renewed focus on SAPIEN TAVR platform durability. Challenges include higher-than-expected tax rates and increased strategic spending on patient access initiatives, though these are expected to moderate in 2026.
What To Expect From Artivion's (AORT) Q4 Earnings
Artivion (AORT) is set to report its Q4 earnings this Thursday. Analysts project a 20.2% year-on-year revenue growth to $117 million and adjusted earnings of $0.18 per share. The company has a history of exceeding revenue estimates, and recent peer performance in the healthcare equipment sector offers mixed signals.
Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Strategic Investments
Edwards Lifesciences Corp (EW) reported strong Q4 2025 results with an 11.6% increase in sales and 10.7% for the full year, driven by robust growth in its TAVR and TMTT segments. Despite challenges like higher spending on patient access initiatives and one-time charges impacting EPS, the company maintains a positive outlook with confident 2026 sales and EPS guidance. CEO Bernard Zovighian and CFO Scott Ullem detailed strategic investments and market dynamics, particularly in TAVR and future growth opportunities like the LAA market.
Edwards Lifesciences (EW) Earnings Transcript
Edwards Lifesciences reported strong Q4 and full-year 2025 results, with double-digit revenue growth driven by their structural heart strategy, particularly TAVR and TMTT product groups. The company is confident in its 2026 sales and EPS guidance, anticipating continued growth from new therapies, expanded indications, and positive clinical evidence, while maintaining a focus on strategic investments and share repurchases.
Edwards Lifesciences (EW) Earnings Transcript
Edwards Lifesciences reported strong Q4 and full-year 2025 results, with total revenue reaching $1.57 billion, marking an 11.6% year-over-year growth. The company saw significant growth across its TAVR, TMTT, and Surgical product groups, exceeding $1 billion in surgical sales for the first time. Despite lower-than-expected adjusted EPS due to increased spending on patient access initiatives and a higher tax rate, management expressed confidence in its 2026 sales and EPS guidance, highlighting robust growth catalysts and strategic R&D advancements.
